Search Results - "Rayford, Austin"

Targeting AXL cellular networks in kidney fibrosis by Grøndal, Sturla M., Blø, Magnus, Nilsson, Linn I. H., Rayford, Austin J., Jackson, Akil, Gausdal, Gro, Lorens, James B.

“…Introduction The incidence of chronic kidney disease (CKD) is increasing, in parallel with risk factors including obesity and diabetes mellitus. AXL plays a…”
Get full text

AXL Targeting Abrogates Autophagic Flux and Induces Immunogenic Cell Death in Drug-Resistant Cancer Cells by Lotsberg, Maria L, Wnuk-Lipinska, Katarzyna, Terry, Stéphane, Tan, Tuan Zea, Lu, Ning, Trachsel-Moncho, Laura, Røsland, Gro V, Siraji, Muntequa I, Hellesøy, Monica, Rayford, Austin, Jacobsen, Kirstine, Ditzel, Henrik J, Vintermyr, Olav K, Bivona, Trever G, Minna, John, Brekken, Rolf A, Baguley, Bruce, Micklem, David, Akslen, Lars A, Gausdal, Gro, Simonsen, Anne, Thiery, Jean Paul, Chouaib, Salem, Lorens, James B, Engelsen, Agnete Svendsen Tenfjord

“…Acquired cancer therapy resistance evolves under selection pressure of immune surveillance and favors mechanisms that promote drug resistance through cell…”
Get more information

AXL expression reflects tumor-immune cell dynamics impacting outcome in non-small cell lung cancer patients treated with immune checkpoint inhibitor monotherapy by Rayford, Austin, Gärtner, Fabian, Ramnefjell, Maria P, Lorens, James B, Micklem, David R, Aanerud, Marianne, Engelsen, Agnete S T

“…AXL receptor expression is proposed to confer immune-checkpoint inhibitor (ICI)-resistance in non-small cell lung cancer (NSCLC) patients. We sought to…”
Get full text

Intrinsic Differences in Spatiotemporal Organization and Stromal Cell Interactions Between Isogenic Lung Cancer Cells of Epithelial and Mesenchymal Phenotypes Revealed by High-Dimensional Single-Cell Analysis of Heterotypic 3D Spheroid Models by Lotsberg, Maria L, Røsland, Gro V, Rayford, Austin J, Dyrstad, Sissel E, Ekanger, Camilla T, Lu, Ning, Frantz, Kirstine, Stuhr, Linda E B, Ditzel, Henrik J, Thiery, Jean Paul, Akslen, Lars A, Lorens, James B, Engelsen, Agnete S T

“…The lack of inadequate preclinical models remains a limitation for cancer drug development and is a primary contributor to anti-cancer drug failures in…”
Get full text

598 Bemcentinib + pembrolizumab show promising efficacy in metastatic NSCLC harbouring mutations associated with poor prognosis: exploratory sub-analysis from the BGBC008 trial (NCT03184571) by Gausdal, Gro, Micklem, David R, Blø, Magnus, Rayford, Austin, Alzhanova, Dina, Madeleine, Noëlly, Taverna, Josephine Amalia, Hung, Chia-Nung, Brekken, Rolf A, Chisamore, Michael, Gorcea-Carson, Claudia, Oliva, Cristina, McCracken, Nigel

“…BackgroundIn NSCLC, mutations in LKB1/STK11, KEAP1, SMARCA4, and KRAS are associated with unfavorable treatment outcomes, regardless of treatment modality.1–4…”
Get full text

362 A PhII study of bemcentinib, a first-in-class selective AXL kinase inhibitor, in combination with pembrolizumab in pts with previously-treated advanced NSCLC: Updated clinical & translational analysis by Spicer, James, Helland, Åslaug, Carcereny, Enric, Arriola, Edurne, Gomez, Manuel Dómine, Trigo Perez, Jose Manuel, Thompson, Jonathan, Strauss, James, Ortega Granados, Ana Laura, Felip, Enriqueta, Schmidt, Emmett, Chisamore, Michael, Madeleine, Noelly, Rayford, Austin, Lorens, Katherine, Siddiqui, Abdul, Gabra, Hani, Nautiyal, Jaya, Micklem, David, Lorens, James, Krebs, Matthew

“…BackgroundAXL is implicated in resistance to immunotherapy. Bemcentinib (BGB324), a first-in-class, oral, selective and potent AXL kinase inhibitor, enhances…”
Get full text

Bemcentinib (Oral AXL Inhibitor) in Combination with Low-Dose Cytarabine Is Well Tolerated and Efficacious in Older Relapsed AML Patients.Updates from the Ongoing Phase II Trial (NCT02488408) and Preliminary Translational Results Indicating Bemcentinib Elicits Anti-AML Immune Responses by Loges, Sonja, Sutamtewagul, Grerk, Heuser, Michael, Chromik, Jörg, Kapp-Schwoerer, Silke, Crugnola, Monica, Di Renzo, Nicola, Lemoli, Roberto M., Mattei, Daniele Giovanni, Ben Batalla, Isabel, Hellesøy, Monica, Waizenegger, Jonas, Janning, Melanie, Imbusch, Charles D., Beumer, Niklas, Rayford, Austin, Nautiyal, Jaya, Berkman-Gottlieb, Tzivia, Micklem, David, Gabra, Hani, Gorcea-Carson, Claudia, Lorens, James B., Fiedler, Walter, Alvarado, Yesid, Gjertsen, Bjorn T., Rieckmann, Lisa-Marie

“…Background: Relapsed (REL) & refractory (REF) r/r AML pts unsuitable for intensive therapy (IT) due to age or co-morbidities, have limited treatment options…”
Get full text

AXL targeting restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through expansion of TCF1+ CD8 T cells by Li, Huiyu, Liu, Zhida, Liu, Longchao, Zhang, Hongyi, Han, Chuanhui, Girard, Luc, Park, Hyunsil, Zhang, Anli, Dong, Chunbo, Ye, Jianfeng, Rayford, Austin, Peyton, Michael, Li, Xiaoguang, Avila, Kimberley, Cao, Xuezhi, Hu, Shuiqing, Alam, Md Maksudul, Akbay, Esra A., Solis, Luisa M., Behrens, Carmen, Hernandez-Ruiz, Sharia, Lu, Wei, Wistuba, Ignacio, Heymach, John V., Chisamore, Michael, Micklem, David, Gabra, Hani, Gausdal, Gro, Lorens, James B., Li, Bo, Fu, Yang-Xin, Minna, John D., Brekken, Rolf A.

“…Mutations in STK11/LKB1 in non-small cell lung cancer (NSCLC) are associated with poor patient responses to immune checkpoint blockade (ICB), and introduction…”
Get full text

Abstract 3245: AXL as a therapeutic target in STK11 mutant NSCLC by Blø, Magnus, Rayford, Austin, Madeleine, Noëlly, Gärtner, Fabian, Bohan, Dana, Ruggio, Natalie, Li, Huiyu, Girard, Luc, Brekken, Rolf, Minna, John, Ånerud, Marianne, Maury, Wendy, Gorcea-Carson, Claudia, Gausdal, Gro, Micklem, David R., McCracken, Nigel

“…Abstract STK11 (LKB1) is a tumor suppressor, and loss-of-function mutations contribute to tumorigenesis. Mutations in the STK11 gene (STK11m) are present in ~…”
Get full text

Decoding cancer's camouflage: epithelial-mesenchymal plasticity in resistance to immune checkpoint blockade by Lotsberg, Maria L, Rayford, Austin, Thiery, Jean Paul, Belleggia, Giuliana, D'Mello Peters, Stacey, Lorens, James B, Chouaib, Salem, Terry, Stephane, Engelsen, Agnete S T

“…Epithelial-mesenchymal plasticity (EMP) of cancer cells contributes to cancer cell heterogeneity, and it is well established that EMP is a critical determinant…”
Get full text